Open Calls for Input and Feedback

Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.

At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.

Draft Recommendations

dostarlimab (Jemperli)

Therapeutic Area: Endometrial cancer
Draft recommendations posted for stakeholder feedback: April 4, 2024
End of feedback period: April 18, 2024
Draft Recommendation
 

Submit Feedback

 

cemiplimab (Libtayo)

Therapeutic Area: Locally advanced or metastatic NSCLC (first line)
Draft recommendations posted for stakeholder feedback: April 4, 2024
End of feedback period: April 18, 2024
Draft Recommendation
 

Submit Feedback

 

Open Calls for Patient and Clinician Input

Therapeutic Area
Therapeutic Area: Hereditary Angioedema
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Iron deficiency anemia
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Advanced Systemic Mastocytosis
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Activated phosphoinositide 3 kinase delta syndrome
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Relapsed or refractory multiple myeloma
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: ALK-positive NSCLC
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Gastrointestinal cancer
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Polyneuropathy in hereditary transthyretin-mediated amyloidosis
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Pulmonary arterial hypertension (WHO group 1)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Paroxysmal nocturnal hemoglobinuria (PNH)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed: